ES2740548T3 - Método para aumentar el éxito de implantación en fertilización asistida - Google Patents
Método para aumentar el éxito de implantación en fertilización asistida Download PDFInfo
- Publication number
- ES2740548T3 ES2740548T3 ES13740258T ES13740258T ES2740548T3 ES 2740548 T3 ES2740548 T3 ES 2740548T3 ES 13740258 T ES13740258 T ES 13740258T ES 13740258 T ES13740258 T ES 13740258T ES 2740548 T3 ES2740548 T3 ES 2740548T3
- Authority
- ES
- Spain
- Prior art keywords
- endometrial
- state
- uterine
- cells
- unk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 106
- 238000002513 implantation Methods 0.000 title claims abstract description 58
- 230000004720 fertilization Effects 0.000 title claims description 20
- 230000002357 endometrial effect Effects 0.000 claims abstract description 207
- 210000004027 cell Anatomy 0.000 claims abstract description 124
- 230000014509 gene expression Effects 0.000 claims abstract description 83
- 102000003812 Interleukin-15 Human genes 0.000 claims abstract description 80
- 108090000172 Interleukin-15 Proteins 0.000 claims abstract description 78
- 102000003810 Interleukin-18 Human genes 0.000 claims abstract description 78
- 108090000171 Interleukin-18 Proteins 0.000 claims abstract description 78
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims abstract description 54
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims abstract description 54
- 230000000694 effects Effects 0.000 claims abstract description 40
- 210000004696 endometrium Anatomy 0.000 claims abstract description 36
- 230000007115 recruitment Effects 0.000 claims abstract description 33
- 230000035772 mutation Effects 0.000 claims abstract description 24
- 101100046559 Mus musculus Tnfrsf12a gene Proteins 0.000 claims abstract description 19
- 230000035800 maturation Effects 0.000 claims abstract description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 32
- 239000003246 corticosteroid Substances 0.000 claims description 24
- 238000011156 evaluation Methods 0.000 claims description 24
- 239000003153 chemical reaction reagent Substances 0.000 claims description 21
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 19
- 238000005516 engineering process Methods 0.000 claims description 17
- 238000000338 in vitro Methods 0.000 claims description 17
- 230000029849 luteinization Effects 0.000 claims description 16
- 230000000638 stimulation Effects 0.000 claims description 15
- 229960001334 corticosteroids Drugs 0.000 claims description 14
- 230000002159 abnormal effect Effects 0.000 claims description 13
- 210000000287 oocyte Anatomy 0.000 claims description 12
- 208000000509 infertility Diseases 0.000 claims description 11
- 230000036512 infertility Effects 0.000 claims description 11
- 231100000535 infertility Toxicity 0.000 claims description 11
- 230000002611 ovarian Effects 0.000 claims description 11
- 229960003387 progesterone Drugs 0.000 claims description 8
- 239000000186 progesterone Substances 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 6
- 229940088597 hormone Drugs 0.000 claims description 6
- 239000005556 hormone Substances 0.000 claims description 6
- 230000000770 proinflammatory effect Effects 0.000 claims description 6
- 238000011084 recovery Methods 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 230000036541 health Effects 0.000 claims description 5
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 4
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims description 4
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims description 4
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 4
- 229960002897 heparin Drugs 0.000 claims description 4
- 229920000669 heparin Polymers 0.000 claims description 4
- 230000003054 hormonal effect Effects 0.000 claims description 4
- 229940084986 human chorionic gonadotropin Drugs 0.000 claims description 4
- 230000006041 cell recruitment Effects 0.000 claims description 3
- 230000004043 responsiveness Effects 0.000 claims description 3
- 229940028435 intralipid Drugs 0.000 claims description 2
- 239000007800 oxidant agent Substances 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 210000000822 natural killer cell Anatomy 0.000 abstract description 31
- 102000004127 Cytokines Human genes 0.000 description 48
- 108090000695 Cytokines Proteins 0.000 description 48
- 230000035935 pregnancy Effects 0.000 description 27
- 239000000523 sample Substances 0.000 description 26
- 210000001161 mammalian embryo Anatomy 0.000 description 23
- 102100024584 Tumor necrosis factor ligand superfamily member 12 Human genes 0.000 description 22
- 101710097155 Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 description 22
- 108020004999 messenger RNA Proteins 0.000 description 21
- 239000000090 biomarker Substances 0.000 description 19
- 238000012546 transfer Methods 0.000 description 17
- 230000004913 activation Effects 0.000 description 16
- 210000002257 embryonic structure Anatomy 0.000 description 16
- 108010054017 Granulocyte Colony-Stimulating Factor Receptors Proteins 0.000 description 15
- 102000013462 Interleukin-12 Human genes 0.000 description 14
- 238000011529 RT qPCR Methods 0.000 description 14
- 102100039622 Granulocyte colony-stimulating factor receptor Human genes 0.000 description 13
- 108010065805 Interleukin-12 Proteins 0.000 description 12
- 102000004889 Interleukin-6 Human genes 0.000 description 11
- 108090001005 Interleukin-6 Proteins 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 10
- 201000000736 Amenorrhea Diseases 0.000 description 9
- 206010001928 Amenorrhoea Diseases 0.000 description 9
- 231100000540 amenorrhea Toxicity 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000003013 cytotoxicity Effects 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 229940011871 estrogen Drugs 0.000 description 7
- 239000000262 estrogen Substances 0.000 description 7
- 238000003018 immunoassay Methods 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- 238000000018 DNA microarray Methods 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 6
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 6
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 6
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 238000004166 bioassay Methods 0.000 description 6
- 238000001574 biopsy Methods 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940028334 follicle stimulating hormone Drugs 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000002865 immune cell Anatomy 0.000 description 6
- 230000016087 ovulation Effects 0.000 description 6
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 238000007405 data analysis Methods 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 229960005309 estradiol Drugs 0.000 description 5
- 229930182833 estradiol Natural products 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 238000009597 pregnancy test Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 102000003390 tumor necrosis factor Human genes 0.000 description 5
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 4
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 210000005168 endometrial cell Anatomy 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000008774 maternal effect Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000027758 ovulation cycle Effects 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 102100022289 60S ribosomal protein L13a Human genes 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 101000681240 Homo sapiens 60S ribosomal protein L13a Proteins 0.000 description 3
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 3
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 3
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 3
- 102000003992 Peroxidases Human genes 0.000 description 3
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000032692 embryo implantation Effects 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000009027 insemination Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 201000004535 ovarian dysfunction Diseases 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 206010036601 premature menopause Diseases 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 3
- 210000003289 regulatory T cell Anatomy 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 208000000995 spontaneous abortion Diseases 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 208000037408 Device failure Diseases 0.000 description 2
- 208000007984 Female Infertility Diseases 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010021928 Infertility female Diseases 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108010017515 Interleukin-12 Receptors Proteins 0.000 description 2
- 108010017535 Interleukin-15 Receptors Proteins 0.000 description 2
- 102000004557 Interleukin-18 Receptors Human genes 0.000 description 2
- 108010017537 Interleukin-18 Receptors Proteins 0.000 description 2
- 108010092694 L-Selectin Proteins 0.000 description 2
- 102000016551 L-selectin Human genes 0.000 description 2
- 208000007466 Male Infertility Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 102100030173 Muellerian-inhibiting factor Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 description 2
- 102100023616 Neural cell adhesion molecule L1-like protein Human genes 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 210000002459 blastocyst Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000001461 cytolytic effect Effects 0.000 description 2
- 230000016117 decidualization Effects 0.000 description 2
- 230000001687 destabilization Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 229940083544 estradiol 2 mg Drugs 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 210000001667 gestational sac Anatomy 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000037417 hyperactivation Effects 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 230000007365 immunoregulation Effects 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 210000002993 trophoblast Anatomy 0.000 description 2
- 210000000685 uterine artery Anatomy 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 102100034608 Angiopoietin-2 Human genes 0.000 description 1
- 108010048036 Angiopoietin-2 Proteins 0.000 description 1
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000003685 Fibroblast growth factor 14 Human genes 0.000 description 1
- 108090000046 Fibroblast growth factor 14 Proteins 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 description 1
- 101000830598 Homo sapiens Tumor necrosis factor ligand superfamily member 12 Proteins 0.000 description 1
- 241000762515 Hydrosalpinx Species 0.000 description 1
- 206010020608 Hypercoagulation Diseases 0.000 description 1
- 206010058359 Hypogonadism Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 208000035752 Live birth Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 108010004217 Natural Cytotoxicity Triggering Receptor 1 Proteins 0.000 description 1
- 102100032870 Natural cytotoxicity triggering receptor 1 Human genes 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- MKPDWECBUAZOHP-AFYJWTTESA-N Paramethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O MKPDWECBUAZOHP-AFYJWTTESA-N 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 206010052649 Primary hypogonadism Diseases 0.000 description 1
- 230000021839 RNA stabilization Effects 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 208000007893 Salpingitis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 206010042573 Superovulation Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 208000032594 Vascular Remodeling Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000006481 angiogenic pathway Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000868 anti-mullerian hormone Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013479 data entry Methods 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 208000002566 gonadal dysgenesis Diseases 0.000 description 1
- 208000030843 hydrosalpinx Diseases 0.000 description 1
- 230000008088 immune pathway Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 229940118179 lovenox Drugs 0.000 description 1
- 230000000938 luteal effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 229960001207 micronized progesterone Drugs 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010295 mobile communication Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003990 molecular pathway Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- -1 nucleotide triphosphates Chemical class 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000028742 placenta development Effects 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000000136 postovulatory effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 229940102535 prednisone 20 mg Drugs 0.000 description 1
- 208000017942 premature ovarian failure 1 Diseases 0.000 description 1
- 208000016685 primary ovarian failure Diseases 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- PXGPLTODNUVGFL-UHFFFAOYSA-N prostaglandin F2alpha Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CC=CCCCC(O)=O PXGPLTODNUVGFL-UHFFFAOYSA-N 0.000 description 1
- XKMLYUALXHKNFT-UHFFFAOYSA-N rGTP Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O XKMLYUALXHKNFT-UHFFFAOYSA-N 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 201000005665 thrombophilia Diseases 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 210000000251 trophoblastic cell Anatomy 0.000 description 1
- 238000009810 tubal ligation Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1089—Design, preparation, screening or analysis of libraries using computer algorithms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/367—Infertility, e.g. sperm disorder, ovulatory dysfunction
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Gynecology & Obstetrics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Reproductive Health (AREA)
- Medicinal Chemistry (AREA)
- Pregnancy & Childbirth (AREA)
- Pathology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12177377.4A EP2687851A1 (en) | 2012-07-20 | 2012-07-20 | Method for increasing implantation success in assisted fertilization |
| PCT/EP2013/065355 WO2014013079A1 (en) | 2012-07-20 | 2013-07-19 | Method for increasing implantation success in assisted fertilization |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2740548T3 true ES2740548T3 (es) | 2020-02-05 |
Family
ID=48874275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13740258T Active ES2740548T3 (es) | 2012-07-20 | 2013-07-19 | Método para aumentar el éxito de implantación en fertilización asistida |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10450561B2 (https=) |
| EP (2) | EP2687851A1 (https=) |
| JP (1) | JP6411340B2 (https=) |
| CN (1) | CN104603622B (https=) |
| AU (1) | AU2013291941B2 (https=) |
| BR (1) | BR112015001157B1 (https=) |
| CA (1) | CA2879467C (https=) |
| DK (1) | DK2877856T3 (https=) |
| ES (1) | ES2740548T3 (https=) |
| HU (1) | HUE046835T2 (https=) |
| IL (1) | IL236824B (https=) |
| PL (1) | PL2877856T3 (https=) |
| PT (1) | PT2877856T (https=) |
| RU (1) | RU2730873C2 (https=) |
| SI (1) | SI2877856T1 (https=) |
| WO (1) | WO2014013079A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114927178A (zh) * | 2015-06-12 | 2022-08-19 | 格尼亚Ip控股私人有限公司 | 患者和生物样本识别和追踪的方法和系统 |
| WO2017054038A1 (en) | 2015-09-30 | 2017-04-06 | Prince Henry's Institute Of Medical Research Trading As The Hudson Institute Of Medical Research | A method of treatment and prognosis |
| CN105784983B (zh) * | 2016-01-13 | 2017-10-31 | 深圳中山生殖与遗传研究所 | 一种评估子宫内膜容受性的试剂盒及其使用方法 |
| CZ2017255A3 (cs) | 2017-05-04 | 2018-11-14 | Zentiva, K.S. | Filmem potažené tablety Deferasiroxu |
| EP3914915A1 (en) * | 2019-01-25 | 2021-12-01 | Fertility Lab Sciences, LLC | Uterine endometrial fluid for prediction of success in fertility treatment |
| CN110042156B (zh) | 2019-04-22 | 2021-12-28 | 苏州亿康医学检验有限公司 | 一种判断子宫内膜容受性的方法及其应用 |
| CN110148446B (zh) * | 2019-05-21 | 2023-06-16 | 重庆市柏玮熠科技有限公司 | Ivf样本核对系统 |
| CN114599798A (zh) * | 2019-06-25 | 2022-06-07 | 哈德逊医学研究所 | 预测子宫内膜容受性的方法 |
| GB201911947D0 (en) * | 2019-08-20 | 2019-10-02 | Univ Warwick | Miscarriage biomarkers |
| RU2732432C1 (ru) * | 2020-03-31 | 2020-09-16 | Федеральное государственное бюджетное учреждение "Уральский научно-исследовательский институт охраны материнства и младенчества" Министерства здравоохранения Российской Федерации (ФГБУ "НИИ ОММ" Минздрава России) | Способ оценки эндометриальной дисфункции у женщин с первичным эндометриоз-ассоциированным бесплодием |
| CN111624354A (zh) * | 2020-06-05 | 2020-09-04 | 佛山迪安医学检验实验室有限公司 | 一种诊断试剂盒及诊断方法 |
| CN111772682B (zh) * | 2020-07-10 | 2021-08-13 | 北京大学第三医院（北京大学第三临床医学院） | 预测受试者出现卵巢储备新变化年限的系统和方法 |
| CN111778326B (zh) * | 2020-07-14 | 2021-10-22 | 和卓生物科技（上海）有限公司 | 用于子宫内膜容受性评估的基因标志物组合及其应用 |
| RU2748191C1 (ru) * | 2021-01-21 | 2021-05-20 | Мекан Рахимбердыевич Оразов | Способ определения степени выраженности хронического эндометрита у женщин с маточным фактором бесплодия после неудачного экстракорпорального оплодотворения в анамнезе (варианты) |
| EP4407626A1 (fr) * | 2023-01-30 | 2024-07-31 | Sofia | Procédé de génération de recommandations diagnostiques et/ou thérapeutiques en fertilité |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GR1004154B (el) * | 2001-05-21 | 2003-02-20 | Μεθοδος διερευνησης του ενδομητριου με εξετασεις που εφαρμοζονται επι του ιστου αποπεπτωκοτος ενδομητριου (ιστου περιοδου) | |
| US7175990B2 (en) | 2002-02-26 | 2007-02-13 | The Regents Of The University Of California | Method of determining endometrial receptivity |
| US20100150862A1 (en) * | 2006-12-07 | 2010-06-17 | Schering Corporation | Methods of modulating maternal-fetal tolerance |
| CN105224827B (zh) * | 2008-07-01 | 2019-12-24 | 小利兰·斯坦福大学托管委员会 | 用于发展ivf治疗协议的分析数据的计算机系统和存储介质 |
| WO2010010201A1 (es) | 2008-07-22 | 2010-01-28 | Equipo Ivi Investigacion Sl | Perfil de expresion genetica como marcador de la receptividad endometrial |
| WO2011000805A1 (en) * | 2009-06-29 | 2011-01-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Biomarkers of oocyte competency and method of use |
| EP2348318A1 (en) | 2010-01-21 | 2011-07-27 | Equipo Ivi Investigación, S.L. | Diagnostic method for endometrial receptivity |
| JP6219164B2 (ja) * | 2010-05-27 | 2017-10-25 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 患者の子宮内膜の受容性を評価するための方法 |
| BR112013000879A2 (pt) * | 2010-07-13 | 2016-05-17 | Univfy Inc | método de avaliação do risco de nascimento múltiplos em travamentos para infertilidade |
| RU2444315C1 (ru) * | 2010-09-03 | 2012-03-10 | Михаил Григорьевич Шнейдерман | Способ повышения возможности удачной имплантации эмбриона к эндометрию полости матки |
-
2012
- 2012-07-20 EP EP12177377.4A patent/EP2687851A1/en not_active Withdrawn
-
2013
- 2013-07-19 CA CA2879467A patent/CA2879467C/en active Active
- 2013-07-19 BR BR112015001157-8A patent/BR112015001157B1/pt active IP Right Grant
- 2013-07-19 DK DK13740258.2T patent/DK2877856T3/da active
- 2013-07-19 EP EP13740258.2A patent/EP2877856B1/en active Active
- 2013-07-19 HU HUE13740258A patent/HUE046835T2/hu unknown
- 2013-07-19 CN CN201380046019.3A patent/CN104603622B/zh active Active
- 2013-07-19 WO PCT/EP2013/065355 patent/WO2014013079A1/en not_active Ceased
- 2013-07-19 PT PT13740258T patent/PT2877856T/pt unknown
- 2013-07-19 PL PL13740258T patent/PL2877856T3/pl unknown
- 2013-07-19 ES ES13740258T patent/ES2740548T3/es active Active
- 2013-07-19 JP JP2015522119A patent/JP6411340B2/ja active Active
- 2013-07-19 RU RU2016106004A patent/RU2730873C2/ru not_active Application Discontinuation
- 2013-07-19 US US14/415,987 patent/US10450561B2/en active Active
- 2013-07-19 AU AU2013291941A patent/AU2013291941B2/en active Active
- 2013-07-19 SI SI201331544T patent/SI2877856T1/sl unknown
-
2015
- 2015-01-20 IL IL236824A patent/IL236824B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| PL2877856T3 (pl) | 2019-11-29 |
| BR112015001157B1 (pt) | 2022-03-29 |
| CA2879467C (en) | 2021-11-09 |
| EP2877856A1 (en) | 2015-06-03 |
| JP2015531057A (ja) | 2015-10-29 |
| SI2877856T1 (sl) | 2019-11-29 |
| US10450561B2 (en) | 2019-10-22 |
| IL236824B (en) | 2018-06-28 |
| DK2877856T3 (da) | 2019-08-12 |
| WO2014013079A1 (en) | 2014-01-23 |
| EP2877856B1 (en) | 2019-07-10 |
| HK1210835A1 (en) | 2016-05-06 |
| AU2013291941A1 (en) | 2015-02-12 |
| RU2730873C2 (ru) | 2020-08-26 |
| RU2016106004A (ru) | 2017-12-08 |
| BR112015001157A2 (https=) | 2017-08-15 |
| CN104603622B (zh) | 2017-08-01 |
| US20150184152A1 (en) | 2015-07-02 |
| CA2879467A1 (en) | 2014-01-23 |
| HUE046835T2 (hu) | 2020-03-30 |
| AU2013291941B2 (en) | 2019-05-02 |
| PT2877856T (pt) | 2019-08-21 |
| EP2687851A1 (en) | 2014-01-22 |
| CN104603622A (zh) | 2015-05-06 |
| JP6411340B2 (ja) | 2018-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2740548T3 (es) | Método para aumentar el éxito de implantación en fertilización asistida | |
| Blockeel et al. | Should we still perform fresh embryo transfers in ART? | |
| Ku et al. | Serum progesterone distribution in normal pregnancies compared to pregnancies complicated by threatened miscarriage from 5 to 13 weeks gestation: a prospective cohort study | |
| Mascarenhas et al. | Management of recurrent implantation failure: British Fertility Society policy and practice guideline | |
| Katz-Jaffe et al. | Association of abnormal ovarian reserve parameters with a higher incidence of aneuploid blastocysts | |
| Bourdon et al. | The deferred embryo transfer strategy improves cumulative pregnancy rates in endometriosis-related infertility: A retrospective matched cohort study | |
| Huang et al. | Assisted reproductive techniques | |
| Jie et al. | Association of assisted reproductive technology with adverse pregnancy outcomes | |
| Mikolajczyk et al. | The impact of leukemia inhibitory factor in uterine flushing on the reproductive potential of infertile women–a prospective study | |
| Wu et al. | Bone morphogenetic protein-15 in follicle fluid combined with age may differentiate between successful and unsuccessful poor ovarian responders | |
| Zhou et al. | Association between serum estradiol levels prior to progesterone administration in artificial frozen–thawed blastocyst transfer cycles and live birth rate: a retrospective study | |
| Awonuga et al. | Determinants of embryo implantation: roles of the endometrium and embryo in implantation success | |
| Moshkalova et al. | Endometrial thickness and live birth rates after IVF: a systematic review | |
| Duhig et al. | Fetal fibronectin as a predictor of spontaneous preterm labour in asymptomatic women with a cervical cerclage | |
| Dumancic et al. | Histopathologic characteristics of term placentas in singleton pregnancies in women with endometriosis-related infertility after ART treatment: case-control study | |
| Funghi et al. | Placental and maternal serum activin A in spontaneous and induced labor in late-term pregnancy | |
| Brandao et al. | Shared IVF among female couples: clinical outcomes of the reception of oocytes from the partner (ROPA) method | |
| Ibis et al. | Testicular sperm retrieval for intracytoplasmic sperm injection: when to consider it after unsuccessful intracytoplasmic sperm injection with ejaculated sperm? | |
| Simpson et al. | Peri‐implantation cytokine profile differs between singleton and twin IVF pregnancies | |
| Wong et al. | Do uterine natural killer cell numbers in peri-implantation endometrium predict hypertensive disorder in pregnancy in women with a history of reproductive failure? | |
| Labarta et al. | Midluteal serum progesterone levels in modified natural cycles for embryo transfer: a prospective blinded study | |
| Zhang et al. | Establishment and validation of a nomogram for subsequent first-cycle live births in patients diagnosed with recurrent implantation failure: a population-based analysis | |
| George et al. | The role of reproductive immunology in recurrent pregnancy loss and repeated implantation failure | |
| HK1210835B (en) | Method for increasing implantation success in assisted fertilization | |
| Ledee et al. | Using endometrial immune profiling in young IVF patients: implantation rates improved for morphologically sub-optimal embryos |